ライフサイエンスコーパス: NYHA

1 NYHA functional classification, QOL, and clinical compos

2 NYHA IV subjects required more hemodynamic support, were

3 NYHA status improved by one class in 34% of iloprost ver

4 I HR: 0.76; 95% CI: 0.65 to 0.90; p = 0.001; NYHA functional class III HR: 1.06; 95% CI: 0.86 to 1.31

5 (NYHA) class (NYHA I versus NYHA IV; P=0.01; NYHA I versus III; P=0.19; NYHA I versus II; P=0.55), co

6 primary endpoint were male sex (p = 0.022), NYHA functional class III or IV (p < 0.001), and peak ao

7 that 76% of patients improved by at least 1 NYHA functional class with 88% in NYHA functional class

8 NYHA IV (n=111) and NYHA II and III (n=1254) NYHA IV had lower left ventricular ejection fraction; mo

9 NYHA IV; P=0.01; NYHA I versus III; P=0.19; NYHA I versus II; P=0.55), concomitant revascularization

10 nges in post-exercise LVOT gradient, pVO(2), NYHA class, Kansas City Cardiomyopathy Questionnaire-Cli

11 % male; 64% NYHA functional class II and 36% NYHA functional class III/IV).

12 Association [NYHA] functional class II: 42%; NYHA functional class III: 28%; and NYHA functional clas

13 ry of heart failure (odds ratio [OR], 15.5), NYHA functional class > or =2 (OR, 5.4), and decreased s

14 baseline (median age 59 years; 71% male; 64% NYHA functional class II and 36% NYHA functional class I

15 nts experienced greater improvement in 6MHW, NYHA functional class, and QoL at six months compared to

16 F HR: 0.97; 95% CI: 0.79 to 1.20; p = 0.802; NYHA functional class II HR: 0.76; 95% CI: 0.65 to 0.90;

17 (55% idiopathic PAH, 45% associated PAH, 94% NYHA class III, and mean baseline 6-MWD of 335 m) were r

18 After ablation, NYHA functional class (3 to 2.5; p < 0.05) and LVOT grad

19 t main coronary artery disease, and advanced NYHA heart failure class among VA patients undergoing CA

20 dysfunction were more pronounced in advanced NYHA classes (early mitral inflow velocity/early diastol

21 Those in more advanced NYHA functional classes (III and IV; n = 136) were older

22 were independently associated with advanced NYHA class.

23 ctive of increased operative risk to be age, NYHA functional class, concomitant procedures, and previ

24 Among patients with HCM, age, NYHA functional class, family history of sudden death (F

25 opensity score for receiving treatment, age, NYHA functional class, and ejection fraction.

26 h outcomes being significantly higher in all NYHA classes.

27 e devices should be considered in ambulatory NYHA class IV HF patients similar to those enrolled in C

28 uency ablation can be safely performed among NYHA IV patients.

29 By multivariate Cox analysis, NYHA functional class was independently associated with

30 Following Cox regression analysis, NYHA functional class (III vs. II; p < 0.05) remained th

31 .05 [1.97-6.59] per 1% change, P=0.019), and NYHA II to IV symptoms (odds ratio, 2.16 [1.65-3.18]; P=

32 cant differences between NYHA IV (n=111) and NYHA II and III (n=1254) NYHA IV had lower left ventricu

33 II: 42%; NYHA functional class III: 28%; and NYHA functional class IV: 4%).

34 central vs. 91.7% noncentral, p = 0.679; and NYHA functional class >II, 21.1% vs. 0%, p = 0.128) did

35 th (MR </=2, 96.0% vs. 96.6%, p = 0.866, and NYHA functional class </=II, 81.6% vs. 90.0%, p = 0.335)

36 tment for randomization assignment, age, and NYHA functional class.

37 so influenced the by the duration of CPB and NYHA III/IV; the impact of these risk factors varied wit

38 gnificantly improved 6-min walk distance and NYHA class at 12 weeks.

39 th severe systolic HF on the basis of EF and NYHA symptom class was assessed (receiver operating char

40 duration, treatment, dose, control, EF, and NYHA classification were extracted by using a standardiz

41 tion, include baseline ejection fraction and NYHA functional class, the number of septal arteries inj

42 , V(E)/V(CO2) slope), ejection fraction, and NYHA functional class (P<0.0001).

43 ved exercise tolerance, quality of life, and NYHA functional classification without an accompanying i

44 METHODS AND NYHA II-IV patients undergoing VT radiofrequency ablatio

45 RS duration of 120 milliseconds or more, and NYHA class II symptoms, CRT-D appears to be economically

46 e H/M, LVEF, B-type natriuretic peptide, and NYHA functional class.

47 All patients are fully saturated and NYHA functional class I at latest clinic visit (0.3 to 8

48 AF ablation, multivalve surgery, and NYHA functional class III/IV were associated with an inc

49 A total of 224 patients with T2DM and NYHA functional class I to II CHF with LVEF < or =45% we

50 ersely affect LVEF in patients with T2DM and NYHA functional class I to II CHF.

51 ion fraction percent <40%) was classified as NYHA functional class I through IV when the AVP level wa

52 ease were higher New York Heart Association (NYHA) class (NYHA I versus NYHA IV; P=0.01; NYHA I versu

53 New York Heart Association (NYHA) class and echocardiography were assessed before an

54 odel showed that New York Heart Association (NYHA) class at baseline and follow-up predicted HFH (haz

55 patients were in New York Heart Association (NYHA) class I or II at 1 year.

56 nds or more, and New York Heart Association (NYHA) class I or II symptoms.

57 ntricular block; New York Heart Association (NYHA) class I, II, or III heart failure; and a left vent

58 21 patients with New York Heart Association (NYHA) class II or III CHF and a left ventricular ejectio

59 New York Heart Association (NYHA) class II through IV CHF patients with an LVEF of <

60 age of 64 years, New York Heart Association (NYHA) class II to IV heart failure, and left ventricular

61 in patients with New York Heart Association (NYHA) class II-III heart failure, left ventricular eject

62 g or greater and New York Heart Association (NYHA) class II-III symptoms were assigned (1:1) to recei

63 fraction <=40%, New York Heart Association (NYHA) class II-III, estimated glomerular filtration rate

64 ication included New York Heart Association (NYHA) class III and IV heart failure, smoking, chronic o

65 in patients with New York Heart Association (NYHA) class III and IV HF.

66 in patients with New York Heart Association (NYHA) class III and IV HF.

67 /=18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced eject

68 articipants with New York Heart Association (NYHA) Class III heart failure symptoms and a previous ad

69 Patients with New York Heart Association (NYHA) class III heart failure, irrespective of the left

70 23 patients were New York Heart Association (NYHA) class III or IV at baseline.

71 2), preoperative New York Heart Association (NYHA) class III or IV heart failure status (14.3% vs 34.

72 white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunctio

73 to patients with New York Heart Association (NYHA) class III/IV symptoms (profile B: HR 2.23, p = 0.0

74 reinfarction, or New York Heart Association (NYHA) class IV heart failure.

75 catheterization, New York Heart Association (NYHA) class, and cardiopulmonary exercise testing.

76 min walk (6 MW), New York Heart Association (NYHA) class, quality of life (QOL), and echocardiographi

77 rsus HT for each New York Heart Association (NYHA) class.

78 testing (pkVO2), New York Heart Association (NYHA) classification, and use of angiotensin-converting

79 Life Quality and New York Heart Association (NYHA) congestive heart failure functional class.

80 s was defined as New York Heart Association (NYHA) functional class > or =III.

81 15 patients with New York Heart Association (NYHA) functional class >/=II and moderate or greater fun

82 with symptomatic New York Heart Association (NYHA) functional class >/=II heart failure due to AL amy

83 01-1.06), higher New York Heart Association (NYHA) functional class (HR 1.50; 95% CI 1.02-2.2), log b

84 0.9 to -0.2) for New York Heart Association (NYHA) functional class (p = 0.007), and 1.7 (0.7 to 2.6)

85 duration of AF, New York Heart Association (NYHA) functional class 1 or 2, smaller left atrial size,

86 associated with New York Heart Association (NYHA) Functional class and the composite outcome (all-ca

87 associated with New York Heart Association (NYHA) functional class and to analyze functional class i

88 LVEF and a poor New York Heart Association (NYHA) functional class are not usually referred for tran

89 rocedural MR and New York Heart Association (NYHA) functional class at 1 month (MR </=2, 96.0% vs. 96

90 on and duration, New York Heart Association (NYHA) functional class at 30 days, and 6-month mortality

91 patients were in New York Heart Association (NYHA) functional class I and 31% were in NYHA functional

92 RS interval, and New York Heart Association (NYHA) functional class I to II heart failure (HF).

93 Stable New York Heart Association (NYHA) functional class II and III systolic HF patients (

94 ion (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerul

95 ad severe TR and New York Heart Association (NYHA) functional class II to IV (mean age 76 +/- 13 year

96 in patients with New York Heart Association (NYHA) functional class II-IV chronic heart failure, left

97 61 subjects with New York Heart Association (NYHA) functional class II/III HF and left ventricular ej

98 AH patients with New York Heart Association (NYHA) functional class III (98%) or IV symptoms and a 6-

99 riteria: current New York Heart Association (NYHA) functional class III or functional class II (patie

100 in patients with New York Heart Association (NYHA) functional class III or IV HF and a prolonged QRS.

101 perceived to be New York Heart Association (NYHA) functional class III or IV.

102 62 patients with New York Heart Association (NYHA) functional class III to IV HF and ejection fractio

103 ) for developing New York Heart Association (NYHA) functional class III to IV symptoms compared to no

104 ine, 83% were in New York Heart Association (NYHA) functional class III to IV, and mean left ventricu

105 New York Heart Association (NYHA) functional class improved in the active treatment

106 New York Heart Association (NYHA) functional class IV HF was an exclusion criterion.

107 erity of MR, and New York Heart Association (NYHA) functional class were compared.

108 l/m(2), advanced New York Heart Association (NYHA) functional class, and age >or=75 years as risk fac

109 The New York Heart Association (NYHA) functional class, angina class, exercise duration,

110 Karnofsky index, New York Heart Association (NYHA) functional class, diastolic blood pressure, estima

111 6-MWD), modified New York Heart Association (NYHA) functional class, hemodynamic parameters, and time

112 re: age, gender, New York Heart Association (NYHA) functional class, left ventricular outflow tract (

113 plications were: New York Heart Association (NYHA) functional class, presence of shock, sinus tachyca

114 ARNI) treatment, New York Heart Association (NYHA) functional class, race, history of hospitalisation

115 tolic volume, or New York Heart Association (NYHA) functional class, yielding hazard ratios between 1

116 by at least one New York Heart Association (NYHA) functional class.

117 ion, assessed by New York Heart Association (NYHA) functional class: I, 136+/-159 pg/mL; II, 338+/-43

118 HF etiology and New York Heart Association (NYHA) functional class: ischemic HF HR: 0.81; 95% CI: 0.

119 failure are the New York Heart Association (NYHA) functional classification and the American Heart A

120 raction (EF) and New York Heart Association (NYHA) functional classification in patients with CHF.

121 ), and change in New York Heart Association (NYHA) functional classification.

122 imate of current New York Heart Association (NYHA) functional status was class 1 in 76%, class 2 in 2

123 n, in particular New York Heart Association (NYHA) I-II.

124 s In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenon

125 ts (>/=60 years; New York Heart Association [NYHA] class II-IV, ischemic systolic HF) randomly assign

126 an American, 42% New York Heart Association [NYHA] class III or IV).

127 cardiomyopathy (New York Heart Association [NYHA] functional class I or II) or nonischemic cardiomyo

128 t failure (CHF) (New York Heart Association [NYHA] functional class I to II).

129 echocardiogram (New York Heart Association [NYHA] functional class II: 42%; NYHA functional class II

130 rove Outcomes in New York Heart Association [NYHA] Functional Class III Heart Failure Patients) trial

131 rove Outcomes in New York Heart Association [NYHA] Functional Class III Heart Failure Patients).

132 ith advanced HF (New York Heart Association [NYHA] functional class III or IV and left ventricular ej

133 e heart failure (New York Heart Association [NYHA] functional class III or IV).

134 severe dyspnea (New York Heart Association [NYHA] functional class III or IV: 78%) and/or severe ang

135 ive HF patients (New York Heart Association [NYHA] functional class III to IV) were randomized to rec

136 nctional status (New York Heart Association [NYHA] functional class, 6-min walk distance, patient act

137 F hospitalization with CRT for asymptomatic (NYHA functional class I) patients, risks versus benefits

138 In asymptomatic (NYHA functional class I) patients, HF hospitalization ri

139 , baseline RVSP, together with age, baseline NYHA functional class, pre-operative AF, coronary artery

140 he lower Hb quartiles were more likely to be NYHA functional class IV (p < 0.0001) and have lower pea

141 ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a high

142 There were significant differences between NYHA IV (n=111) and NYHA II and III (n=1254) NYHA IV had

143 omized patients with atrioventricular block, NYHA symptom class I to III heart failure, and left vent

144 T recurrence, and mortality were analyzed by NYHA IV status using Kaplan-Meier analysis and Cox propo

145 lass I or II) or nonischemic cardiomyopathy (NYHA functional class II only), sinus rhythm, an ejectio

146 no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.

147 fter ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).

148 rols (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well a

149 In patients with severe chronic NYHA class III to IV heart failure, the change in ST2 le

150 New York Heart Association functional class (NYHA-FC) and Canadian Cardiovascular Society Angina Clas

151 her New York Heart Association (NYHA) class (NYHA I versus NYHA IV; P=0.01; NYHA I versus III; P=0.19

152 and heart failure patients of corresponding NYHA class (P=NS for each NYHA class).

153 During CRT, NYHA functional class decreased, LV dimensions normalize

154 nd AF, parameters of clinical deterioration (NYHA/WHO functional class, 6-minute walk distance, NT-pr

155 CG, body mass index, hypertension, diabetes, NYHA functional class, ejection fraction, left atrial ap

156 rovement in 6-min hall walk (6MHW) distance, NYHA functional class, and quality of life (QoL) over co

157 s of corresponding NYHA class (P=NS for each NYHA class).

158 At follow-up, 98% of patients were either NYHA class I or II and 87% were in normal sinus rhythm.

159 were required to have chronic heart failure (NYHA II-IV), previous admission for a cardiovascular rea

160 rial fibrillation, congestive heart failure (NYHA II/III), stable coronary artery disease, diabetes t

161 s III/IV and HR, 2.17; 95% CI, 1.54-3.04 for NYHA class II versus class I); other predictors were hea

162 95% confidence interval [CI], 2.74-5.79 for NYHA class III/IV and HR, 2.17; 95% CI, 1.54-3.04 for NY

163 nts (HR=3.20, 95% CI=1.75-5.88) adjusted for NYHA class and other risk factors.

164 ting for left ventricular ejection fraction, NYHA class, age, body mass index, diabetes mellitus, sex

165 It correlates with ventricular function, NYHA classification, and prognosis.

166 infarction (irrespective of their functional NYHA class) and patients within NYHA class II.

167 , and New York Heart Association functional (NYHA) functional class III/IV were independent risk fact

168 All had NYHA functional class III heart failure or greater on pr

169 Most patients had NYHA functional class IV symptoms at baseline.

170 ated activation of p70S6K, PKC-betaII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound

171 ell as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).

172 thy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patie

173 igher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.

174 Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylat

175 A subgroup of patients with advanced HF (NYHA class III/IV) consistently demonstrated improvement

176 nalysis, cocaine use, a lower LVEF, a higher NYHA class, a higher viral load (VL), and a lower CD4 co

177 ng sustainable exercise capacity) and higher NYHA class.

178 significant differences, even in the higher NYHA class groups.

179 Importantly, NYHA IV patients without recurrent VT had similar surviv

180 patients (compared with 9 placebo) improved NYHA functional classification by at least one class (p

181 Although DM was associated with improved NYHA class, 6-minute walk test results did not improve.

182 In NYHA functional class III to IV and age groups </=65 yea

183 t (p < 0.01) occurred after ablation (~5% in NYHA functional classes III and IV, and 8 patients in Ca

184 at least 1 NYHA functional class with 88% in NYHA functional class I or II.

185 plant, and the remaining patients are all in NYHA class 1.

186 The other two patients are in NYHA class 1, 642 and 889 days after implant.

187 Changes in NYHA class (p = 0.10) and QOL (p = 0.40) were not statis

188 luated using the 6-min walk test, changes in NYHA functional class, cardiac function, and quality of

189 es showed a clinically important decrease in NYHA class at 6 to 11 months (range, -0.8 to -2.1 classe

190 sponse to CRT with LVEF >45% and decrease in NYHA functional class at 1 year.

191 tly associated with mortality, especially in NYHA IV patients.

192 all-cause mortality and hospitalizations in NYHA class IV patients, with a trend for improved mortal

193 0.8% +/- 6.1%; P < 0.001) and improvement in NYHA class (-0.9 +/- 0.7 vs. -0.5 +/- 0.8; P = 0.02).

194 ricular pacing showed greater improvement in NYHA functional class at 12 months, with 19% improved, 6

195 No additional improvement in NYHA functional class or QoL was seen compared to the si

196 Although improvements in NYHA class were more likely with DM (P<0.001), 6-minute

197 also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of hea

198 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven

199 patients but 1 demonstrated improvements in NYHA functional status (to class II) with pronounced red

200 es HF hospitalizations, and improves LVEF in NYHA functional class I/II HF patients.

201 onitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) trial w

202 onitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients [CHAMPION]; NCT005

203 onitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients trial) analyzed PA

204 Patients in NYHA class I increased from 12 (23%) to 42 (79%) at 12 m

205 th a similar percentage of those patients in NYHA class I/II (73% tilarginine vs 75% placebo; P = .27

206 Noticeably, the proportion of patients in NYHA functional class III at the end of follow-up was 13

207 0.62; P=0.040), which was more pronounced in NYHA classes III and IV.

208 In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion

209 n fraction < or = 35%, particularly those in NYHA class II, as long as the benefits of ICD therapy ob

210 Elimination of recurrent VT in NYHA IV patients may reduce mortality to a level compara

211 of these initial feasibility studies were in NYHA class 4.

212 patients was 25 percent; 70 percent were in NYHA class II, and 30 percent were in class III CHF.

213 Of the patients, 88 were in NYHA functional class I or II and 12 were in NYHA functi

214 tial evaluation, all of the patients were in NYHA functional class I or II.

215 ne-year survivors of the SHOCK trial were in NYHA functional class I or II.

216 on (NYHA) functional class I and 31% were in NYHA functional class II; and 18% had atrial fibrillatio

217 NYHA functional class I or II and 12 were in NYHA functional class III.

218 nuloplasty and 25% having CABG alone were in NYHA functional class III/IV.

219 nts (50%) developed progressive worsening in NYHA functional class, and 6 patients (27%) experienced

220 mortality by multivariate analysis included NYHA functional class (III vs. II), estimated glomerular

221 Younger age, increased NYHA class, lower ejection fraction, and less depression

222 ndergoing follow-up CMR, we found an initial NYHA functional class >I as the best independent predict

223 rinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure; NCT00063687).

224 d among New York Heart Association class IV (NYHA IV) heart failure patients.

225 ssociated with shorter duration of AF, lower NYHA class, smaller left atrial size, and absence of lef

226 SV]) and quality-of-life (QoL) measurements (NYHA functional class, Minnesota Living with Heart Failu

227 ith PPH (58 female, age 46+/-2 years, median NYHA class III) between 1996 and 2001 who were followed

228 mproved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients wit

229 t baseline, 18% of patients had a history of NYHA functional class I to III HF (liraglutide: n = 835

230 tients with T2D with or without a history of NYHA functional class I to III HF.

231 ass II (patients who had a recent history of NYHA functional class III); ejection fraction <=35%; sta

232 that these relationships were independent of NYHA class, peak V(O2), and V(E)/V(CO2) slope.

233 lications from thrombolysis, irrespective of NYHA functional class.

234 Management of NYHA Class III heart failure based on home transmission

235 Time to first occurrence of NYHA functional class progression, potentially life-thre

236 We sought to examine the outcomes of NYHA class IV patients enrolled in the Comparison of Med

237 Rates of NYHA class IV heart failure (4.4% vs. 4.5%) and death (9

238 ated with subsequent mortality regardless of NYHA status.

239 subgroup interactions for subgroups based on NYHA functional class and race.

240 he mavacamten group improved by at least one NYHA class (80 of 123 patients in the mavacamten group v

241 oxygen consumption (pVO(2)) and at least one NYHA class reduction or a 3.0 mL/kg per min or greater p

242 )(0) supplementation that reported the EF or NYHA functional class as a primary outcome.

243 01) compared with less symptomatic patients (NYHA class II; n = 57).

244 In nonanemic patients, NYHA functional class improved (p = 0.06).

245 vels <200 pg/ml (66% of which were perceived NYHA functional class III or IV).

246 variables-B-type natriuretic peptide, pkVO2, NYHA, and angiotensin-converting enzyme inhibitor/angiot

247 e to clinical worsening, Borg Dyspnea Score, NYHA functional class, 12-week trough 6MWD, 6-week peak

248 e to clinical worsening, Borg Dyspnea Score, NYHA functional class, and PAH signs and symptoms.

249 monitoring on 104 patients with symptomatic NYHA II to IV heart failure (HFpEF, n=48, peak Vo2=13.9+

250 Of the remaining 498 symptomatic (NYHA functional class II-III) patients, 106 (21.3%) had

251 Among mildly symptomatic (NYHA functional class II) patients, CRT was associated w

252 erage e' and E/e'), and exertional symptoms (NYHA II-IV and peak oxygen consumption).

253 atients with moderate-to-severe HF symptoms (NYHA class > 2), PEC time had good accuracy (AUC, 0.875

254 The NYHA functional class improved significantly in those wi

255 The NYHA functional class substantially improved in both gro

256 The NYHA-FC worsened with time in both rate-control and rhyt

257 sidual confounding analyses and analyzed the NYHA I-II and III-IV subgroups separately.

258 he EF and -0.30 (95% CI: -0.66, 0.06) in the NYHA functional class.

259 In the NYHA I-II subgroup, after adjustment for propensity scor

260 VT, and 1-year mortality were higher in the NYHA IV group, in the context of greater baseline comorb

261 er the AHA/ACC heart failure staging nor the NYHA functional classification system identifies the var

262 ed widely in HF without consideration of the NYHA class and ejection fraction, and without optimizati

263 s of CHF, but they did vary according to the NYHA class.

264 significant improvement was noted, with the NYHA functional class decreasing to 1, exercise duration

265 placement had a similar improvement in their NYHA functional class, septal thickness reduction, LVOT

266 ay reduce mortality to a level comparable to NYHA II and III with arrhythmia recurrence.

267 40% and development of heart failure (HF) to NYHA functional class II to IV over several years; 4) ma

268 months and 79% (DT) at 24 months improved to NYHA functional class I or II.

269 lative risk, 1.6; P=0.02) and progression to NYHA class III or IV or death from heart failure or stro

270 The risk of progression to NYHA class III or IV or death specifically from heart fa

271 showed that BNP was independently related to NYHA class as well as age and left ventricular wall thic

272 evels from the PRAISE-2 heart failure trial (NYHA functional class III-IV; end point, mortality or tr

273 eart Association (NYHA) class (NYHA I versus NYHA IV; P=0.01; NYHA I versus III; P=0.19; NYHA I versu

274 tients alive 30 days after implantation were NYHA class I or II.

275 Preoperatively, 67% of patients were NYHA functional class III or IV and postoperatively, 85%

276 In patients </=80 years of age with NYHA functional class III to IV HF and ejection fraction

277 urrent VT had similar survival compared with NYHA II and III patients with recurrent VT (68% versus 7

278 ses identified 32 biomarkers correlated with NYHA class and 28 predicting outcomes.

279 n ATTR amyloidosis, survival correlated with NYHA functional class, diastolic blood pressure, and use

280 ith DCM, AVP levels correlated directly with NYHA functional class (r2=0.73, P<0.001).

281 d left ventricular systolic dysfunction with NYHA class I, II, or III heart failure.

282 Spironolactone interacted with NYHA (P<0.001).

283 cost-effectiveness of CRT-D in patients with NYHA class I symptoms remains uncertain.

284 Data on patients with NYHA class I symptoms were limited.

285 per QALY gained was $44 531 in patients with NYHA class II heart failure and $58 194 in those with cl

286 In patients with NYHA class II or III CHF and LVEF of 35 percent or less,

287 n plasma aldosterone levels in patients with NYHA class II through IV heart failure.

288 lar mortality and morbidity in patients with NYHA class II to IV heart failure.

289 OMPANION trial randomized 1520 patients with NYHA class III and IV HF to optimal medical therapy, CRT

290 duction in hospitalisation for patients with NYHA class III heart failure who were managed with a wir

291 linical trials including 4,317 patients with NYHA functional class I/II HF was performed.

292 mortality (36%, p < 0.002) in patients with NYHA functional class III and IV heart failure and ventr

293 for ischemic HF patients and for those with NYHA functional class II symptoms at trial enrollment.

294 myocardial infarction (n=919) and those with NYHA II heart failure (n=689)--IMT was associated with a

295 patients (age 71+/-12 years; 28% women) with NYHA I-IV and ejection fraction <40% who were registered

296 r functional NYHA class) and patients within NYHA class II.

297 ablation outcomes of those with and without NYHA IV in the International VT Ablation Center Collabor

298 g per min or greater pVO(2) increase without NYHA class worsening.

299 Presence of AF was associated with worse NYHA-FC (p < 0.0001).

300 Presence of AF was associated with worse NYHA-FC.